Gambacorti-Passerini C - Search Results

1

Synergistic Drug Combinations Prevent Resistance in ALK+ Anaplastic Large Cell Lymphoma.

Arosio G, Sharma GG, Villa M, Mauri M, Crespiatico I, Fontana D, Manfroni C, Mastini C, Zappa M, Magistroni V, Ceccon M, Redaelli S, Massimino L, Garbin A, Lovisa F, Mussolin L, Piazza R, Gambacorti-Passerini C, Mologni L. Arosio G, et al. Cancers (Basel). 2021 Sep 1;13(17):4422. doi: 10.3390/cancers13174422. Cancers (Basel). 2021. PMID: 34503232 Free PMC article.

2

Additive antisense effects of different PNAs on the in vitro translation of the PML/RARalpha gene.

Mologni L, leCoutre P, Nielsen PE, Gambacorti-Passerini C. Mologni L, et al. Nucleic Acids Res. 1998 Apr 15;26(8):1934-8. doi: 10.1093/nar/26.8.1934. Nucleic Acids Res. 1998. PMID: 9518485 Free PMC article.

3

In vitro transcriptional and translational block of the bcl-2 gene operated by peptide nucleic acid.

Mologni L, Nielsen PE, Gambacorti-Passerini C. Mologni L, et al. Biochem Biophys Res Commun. 1999 Oct 22;264(2):537-43. doi: 10.1006/bbrc.1999.1548. Biochem Biophys Res Commun. 1999. PMID: 10529398

4

Inhibition of promyelocytic leukemia (PML)/retinoic acid receptor-alpha and PML expression in acute promyelocytic leukemia cells by anti-PML peptide nucleic acid.

Mologni L, Marchesi E, Nielsen PE, Gambacorti-Passerini C. Mologni L, et al. Cancer Res. 2001 Jul 15;61(14):5468-73. Cancer Res. 2001. PMID: 11454693

5

Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias.

Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L. Gambacorti-Passerini CB, et al. Lancet Oncol. 2003 Feb;4(2):75-85. doi: 10.1016/s1470-2045(03)00979-3. Lancet Oncol. 2003. PMID: 12573349 Review.

6

Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels.

Gambacorti-Passerini C, Piazza R, D'Incalci M. Gambacorti-Passerini C, et al. Blood. 2003 Sep 1;102(5):1933-4; author reply 1934-5. doi: 10.1182/blood-2003-05-1629. Blood. 2003. PMID: 12930735 Free article. No abstract available.

7

Expression, purification, and inhibition of human RET tyrosine kinase.

Mologni L, Sala E, Riva B, Cesaro L, Cazzaniga S, Redaelli S, Marin O, Pasquato N, Donella-Deana A, Gambacorti-Passerini C. Mologni L, et al. Protein Expr Purif. 2005 May;41(1):177-85. doi: 10.1016/j.pep.2005.01.002. Protein Expr Purif. 2005. PMID: 15802236

8

Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity.

Donella-Deana A, Marin O, Cesaro L, Gunby RH, Ferrarese A, Coluccia AM, Tartari CJ, Mologni L, Scapozza L, Gambacorti-Passerini C, Pinna LA. Donella-Deana A, et al. Biochemistry. 2005 Jun 14;44(23):8533-42. doi: 10.1021/bi0472954. Biochemistry. 2005. PMID: 15938644

9

Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease.

Franceschino A, Tornaghi L, Piazza R, Pogliani E, Gambacorti Passerini C. Franceschino A, et al. Haematologica. 2006 Jun;91(6 Suppl):ECR14. Haematologica. 2006. PMID: 16785120 No abstract available.

10

The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years.

Piazza RG, Magistroni V, Franceschino A, Andreoni F, Tornaghi L, Colnaghi F, Corneo G, Pogliani EM, Gambacorti-Passerini C. Piazza RG, et al. Blood Cells Mol Dis. 2006 Sep-Oct;37(2):111-5. doi: 10.1016/j.bcmd.2006.06.002. Epub 2006 Aug 14. Blood Cells Mol Dis. 2006. PMID: 16908206 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

372 results

Search Page

Filters